

Highlights of This Issue 3051

SPECIAL FEATURES

CCR Translations

- 3053 **Does Stage II Colorectal Cancer Need to Be Redefined?**
Axel Grothey
See article p. 3293

Molecular Pathways

- 3056 **Epstein-Barr Virus–Associated B-cell Lymphomas: Pathogenesis and Clinical Outcomes**
Abhik Saha and Erle S. Robertson

Special Report

- 3064 **Recommendations from the iSBTe-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers**
Lisa H. Butterfield, A. Karolina Palucka, Cedrik M. Britten, Madhav V. Dhodapkar, Leif Håkansson, Sylvia Janetzki, Yutaka Kawakami, Thomas-Oliver Kleen, Peter P. Lee, Cristina Maccalli, Holden T. Maecker, Vernon C. Maino, Michele Maio, Anatoli Malyguine, Giuseppe Masucci, Graham Pawelec, Douglas M. Potter, Licia Rivoltini, Lupe G. Salazar, Dolores J. Schendel, Craig L. Slingluff, Jr., Wenru Song, David F. Stroncek, Hideaki Tahara, Magdalena Thurin, Giorgio Trinchieri, Sjoerd H. van Der Burg, Theresa L. Whiteside, Jon M. Wigginton, Francesco Marincola, Samir Khleif, Bernard A. Fox, and Mary L. Disis

HUMAN CANCER BIOLOGY

- 3077 **Connective Tissue Growth Factor Acts as a Therapeutic Agent and Predictor for Peritoneal Carcinomatosis of Colorectal Cancer**
Been-Ren Lin, Cheng-Chi Chang, Robert Jeen-Chen Chen, Yung-Ming Jeng, Jin-Tung Liang, Po-Huang Lee, King-Jen Chang, and Min-Liang Kuo

- 3089 **Knockdown of FLOT1 Impairs Cell Proliferation and Tumorigenicity in Breast Cancer through Upregulation of FOXO3a**
Chuyong Lin, Zhiqiang Wu, Xi Lin, Chunping Yu, Tingting Shi, Yong Zeng, Xi Wang, Jun Li, and Libing Song

- 3100 **B7-H4 Expression in Human Melanoma: Its Association with Patients' Survival and Antitumor Immune Response**
Dagmar Quandt, Eckhard Fiedler, Diana Boettcher, Wolfgang Ch Marsch, and Barbara Seliger

- 3112 **Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells**
Ana R. Jensen, Y. David Saito, Chuanhong Liao, Jinlu Dai, Evan T. Keller, Hikmat Al-Ahmadie, Kelly Dakin-Haché, Peter Usatyuk, Margarit F. Sievert, Gladell P. Paner, Soheil Yala, Gustavo M. Cervantes, Viswanathan Natarajan, Ravi Salgia, and Edwin M. Posadas

- 3123 **Brain-Derived Neurotrophic Factor Promotes Tumorigenesis via Induction of Neovascularization: Implication in Hepatocellular Carcinoma**
Chi-Tat Lam, Zhen-Fan Yang, Chi-Keung Lau, Ka-Ho Tam, Sheung-Tat Fan, and Ronnie T.P. Poon

CANCER THERAPY: PRECLINICAL

- 3134 **Enhancement of T-cell–Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer**
Ruud P.M. Dings, Kieng B. Vang, Karolien Castermans, Flavia Popescu, Yan Zhang, Mirjam G.A. oude Egbrink, Matthew F. Mescher, Michael A. Farrar, Arjan W. Griffioen, and Kevin H. Mayo

- 3146 **Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations**
 Francesco Galimi, Davide Torti, Francesco Sassi, Claudio Isella, Davide Corà, Stefania Gastaldi, Dario Ribero, Andrea Muratore, Paolo Massucco, Dimitrios Siatis, Gianluca Paraluppi, Federica Gonella, Francesca Maione, Alberto Pisacane, Ezio David, Bruno Torchio, Mauro Risio, Mauro Salizzoni, Lorenzo Capussotti, Timothy Perera, Enzo Medico, Maria Flavia Di Renzo, Paolo M. Comoglio, Livio Trusolino, and Andrea Bertotti
- 3157 **Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys**
 Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey, Preeti Trisal, and David M. Goldenberg
- 3170 **Extrahepatic Cancer Suppresses Nuclear Receptor–Regulated Drug Metabolism**
 Marina Kacevska, Michael R. Downes, Rohini Sharma, Ronald M. Evans, Stephen J. Clarke, Christopher Liddle, and Graham R. Robertson
- 3181 **Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response**
 Zhigang Kang, Jun-Jie Chen, Yunkai Yu, Bo Li, Shi-Yong Sun, Baolin Zhang, and Liang Cao
- 3193 **Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor**
 Robert Mallon, Larry R. Feldberg, Judy Lucas, Inder Chaudhary, Christoph Dehnhardt, Efen Delos Santos, Zecheng Chen, Osvaldo dos Santos, Semiramis Ayril-Kaloustian, Aranapakam Venkatesan, and Irwin Hollander
- 3204 **Bortezomib Primes Neuroblastoma Cells for TRAIL-Induced Apoptosis by Linking the Death Receptor to the Mitochondrial Pathway**
 Ivonne Naumann, Roland Kappler, Dietrich von Schweinitz, Klaus-Michael Debatin, and Simone Fulda
- 3219 **HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL⁺ Leukemia Cells *In Vitro* and *In Vivo***
 Tri Nguyen, Yun Dai, Elisa Attkisson, Lora Kramer, Nicholas Jordan, Nguyen Nguyen, Nikhil Kolluri, Markus Muschen, and Steven Grant
- 3233 **Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma**
 Daniela Opel, Ivonne Naumann, Maxi Schneider, Daniela Bertele, Klaus-Michael Debatin, and Simone Fulda
- 3248 **Targeting Autophagy Augments *In Vitro* and *In Vivo* Antimyeloma Activity of DNA-Damaging Chemotherapy**
 Yaozhu Pan, Ying Gao, Liang Chen, Guangxun Gao, Hongjuan Dong, Yang Yang, Baoxia Dong, and Xiequn Chen
- 3259 **Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide**
 Loredana Santo, Teru Hideshima, Diana Cirstea, Madhavi Bandi, Erik A. Nelson, Gullu Gorgun, Scott Rodig, Sonia Vallet, Samantha Pozzi, Kishan Patel, Christine Unitt, Matt Squires, Yiguo Hu, Dharminder Chauhan, Anuj Mahindra, Nikhil C. Munshi, Kenneth C. Anderson, and Noopur Raje
- 3272 **The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic *PIK3CA* Mutations**
 Hiroshi Tanaka, Miyuki Yoshida, Hiromi Tanimura, Toshihiko Fujii, Kiyooki Sakata, Yukako Tachibana, Jun Ohwada, Hirosato Ebiike, Shino Kuramoto, Keiichi Morita, Yasushi Yoshimura, Toshikazu Yamazaki, Nobuya Ishii, Osamu Kondoh, and Yuko Aoki
- 3282 **Comparison of Corticotropin-Releasing Factor, Dexamethasone, and Temozolomide: Treatment Efficacy and Toxicity in U87 and C6 Intracranial Gliomas**
 Maxim A. Moroz, Ruimin Huang, Tatiana Kochetkov, Weiji Shi, Howard Thaler, Elisa de Stanchina, Idoia Gamez, Robert P. Ryan, and Ronald G. Blasberg
- 3293 **Occult Tumor Burden Predicts Disease Recurrence in Lymph Node–Negative Colorectal Cancer**
 Terry Hyslop, David S. Weinberg, Stephanie Schulz, Alan Barkun, and Scott A. Waldman
See commentary p. 3053

IMAGING, DIAGNOSIS, PROGNOSIS

- 3304 **Changes in ¹⁸F-Fluorodeoxyglucose and ¹⁸F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer Treated with Erlotinib**
Linda Mileschkin, Rodney J. Hicks, Brett G.M. Hughes, Paul L.R. Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, and Bernard M. Fine
- 3316 **Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis**
Nigel B. Jamieson, C. Ross Carter, Colin J. McKay, and Karin A. Oien
- 3332 **¹⁸FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer**
Eliot T. McKinley, Joseph E. Bugaj, Ping Zhao, Saffet Guleryuz, Christine Mantis, Prafulla C. Gokhale, Robert Wild, and H. Charles Manning
- 3341 **Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1-ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification**
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Emiko Sugawara, Satoko Hatano, Reimi Asaka, Sakae Okumura, Ken Nakagawa, Hiroyuki Mano, and Yuichi Ishikawa
- 3349 **Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification**
Na Yang, Shun Feng, Kerby Shedden, Xiaolei Xie, Yashu Liu, Charles J. Rosser, David M. Lubman, and Steven Goodison
- 3360 **Blood-Based Gene Expression Signatures in Non-Small Cell Lung Cancer**
Thomas Zander, Andrea Hofmann, Andrea Staratschek-Jox, Sabine Classen, Svenja Debey-Pascher, Daniela Maisel, Sascha Ansén, Moritz Hahn, Marc Beyer, Roman K. Thomas, Birgit Gathof, Cornelia Mauch, Karl-Stefan Delank, Walburga Engel-Riedel, H.-Erich Wichmann, Erich Stoelben, Joachim L. Schultze, and Jürgen Wolf
- 3368 **Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer**
Jone Trovik, Elisabeth Wik, Ingunn M. Stefansson, Janusz Marcickiewicz, Solveig Tingulstad, Anne C. Staff, Tormund S. Njolstad, MoMaTec Study Group, Ingrid Vandenput, Frederic Amant, Lars A. Akslen, and Helga B. Salvesen


CANCER THERAPY: CLINICAL

- 3378 **Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothed**
Tracy Tang, Jean Y. Tang, Dongwei Li, Mike Reich, Christopher A. Callahan, Ling Fu, Robert L. Yauch, Frank Wang, Karen Kotkow, Kris S. Chang, Elana Shpall, Angela Wu, Lee L. Rubin, James C. Marsters, Jr., Ervin H. Epstein, Jr., Ivor Caro, and Frederic J. de Sauvage
- 3388 **Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms**
Beata Holkova, E. Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Ellen Shrader, Neha Talreja, Martha D. Wellons, Kevin T. Hogan, G. David Roodman, Domenico Coppola, Loveleen Kang, Jana Dawson, Robert K. Stuart, Cody Peer, William D. Figg, Sr., Sarah Kolla, Austin Doyle, John Wright, Daniel M. Sullivan, John D. Roberts, and Steven Grant
- 3398 **A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin-Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer**
Heather L. McArthur, Hope Rugo, Benjamin Nulsen, Laura Hawks, Jill Grothusen, Michelle Melisko, Mark Moasser, Matthew Paulson, Tiffany Traina, Sujata Patil, Qin Zhou, Richard Steingart, Chau Dang, Monica Morrow, Peter Cordeiro, Monica Fornier, John Park, Andrew Seidman, Diana Lake, Theresa Gilewski, Maria Theodoulou, Shanu Modi, Gabriella D'Andrea, Nancy Sklarin, Mark Robson, Mary Ellen Moynahan, Steven Sugarman, Jane E. Sealey, John H. Laragh, Carmen Merali, Larry Norton, Clifford A. Hudis, and Maura N. Dickler
- 3408 **MHC Class I-Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer**
Michael A. Morse, Angeles A. Secord, Kimberly Blackwell, Amy C. Hobeika, Gomathinayagam Sinnathamby, Takuya Osada, Julie Hafner, Mohan Philip, Timothy M. Clay, H. Kim Lyerly, and Ramila Philip

3420	<p>Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies David Olmos, Douglas Barker, Rohini Sharma, Andre T. Brunetto, Timothy A. Yap, Anne B. Taegtmeyer, Jorge Barriuso, Hanine Medani, Yan Y. Degenhardt, Alicia J. Allred, Deborah A. Smith, Sharon C. Murray, Thomas A. Lampkin, Mohammed M. Dar, Richard Wilson, Johann S. de Bono, and Sarah P. Blagden</p>	3469	<p>Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer Peter P. Grimminger, Peter Danenberg, Kathrin Dellas, Dirk Arnold, Claus Rödel, Jean-Pascal Machiels, Karin Haustermans, Annelies Debucquoy, Vaneja Velenik, Christine Sempoux, Matej Bracko, Arnulf H. Hölscher, Robert Semrau, Dongyun Yang, Kathleen Danenberg, Heinz-Josef Lenz, and Daniel Vallböhmer</p>
3431	<p>Phase I Studies of CBP501, a G₂ Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors Geoffrey I. Shapiro, Raoul Tibes, Michael S. Gordon, Bryan Y. Wong, Joseph Paul Eder, Mitesh J. Borad, David S. Mendelson, Nicholas J. Vogelzang, Bruno R. Bastos, Glen J. Weiss, Cristian Fernandez, William Sutherland, Hitoshi Sato, William E. Pierceall, David Weaver, Scott Slough, Ernesto Wasserman, Donald W. Kufe, Daniel Von Hoff, Takumi Kawabe, and Sunil Sharma</p>	3478	<p>Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma Xiao-Hong Ma, Shengfu Piao, Dan Wang, Quentin W. McAfee, Katherine L. Nathanson, Julian J. Lum, Lin Z. Li, and Ravi K. Amaravadi</p>
		3490	<p>Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib Patrick G. Morris, Carol Chen, Richard Steingart, Martin Fleisher, Nancy Lin, Beverly Moy, Steven Come, Steven Sugarman, Alyson Abbruzzi, Robert Lehman, Sujata Patil, Maura Dickler, Heather L. McArthur, Eric Winer, Larry Norton, Clifford A. Hudis, and Chau T. Dang</p>
PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE			
3443	<p>Molecular Karyotypes of Hodgkin and Reed–Sternberg Cells at Disease Onset Reveal Distinct Copy Number Alterations in Chemosensitive versus Refractory Hodgkin Lymphoma Marilyn L. Slovak, Victoria Bedell, Ya-Hsuan Hsu, Dolores B. Estrine, Norma J. Nowak, Maria L. Delioukina, Lawrence M. Weiss, David D. Smith, and Stephen J. Forman</p>	3500	<p>Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene Naiyer A. Rizvi, Valerie Rusch, William Pao, Jamie E. Chaft, Marc Ladanyi, Vincent A. Miller, Lee M. Krug, Christopher G. Azzoli, Manjit Bains, Robert Downey, Raja Flores, Bernard Park, Bhuvanesh Singh, Maureen Zakowski, Robert T. Heelan, Ronglai Shen, and Mark G. Kris</p>
3455	<p>Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer Maarten J. Deenen, Jolien Tol, Artur M Burylo, Valerie D. Doodeman, Anthonius de Boer, Andrew Vincent, Henk-Jan Guchelaar, Paul H. M. Smits, Jos H. Beijnen, Cornelis J.A. Punt, Jan H.M. Schellens, and Annemieke Cats</p>		

ABOUT THE COVER

Distribution of actin and MET in PC3 cells stimulated with hepatocyte growth factor. Actin is shown in red, MET is shown in green, and nuclei are shown in blue (DAPI). The yellow areas indicate coexpression of actin and MET suggestive of focal adhesion plaques. For further details, please see Jensen and coworkers on page 3112 in this issue.



Clinical Cancer Research

17 (10)

Clin Cancer Res 2011;17:3051-3506.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/17/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/17/10>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.